Compound Detail
CHEMBL348000
CINCHOPHEN 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL348000 |
| Name | CINCHOPHEN |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | YTRMTPPVNRALON-UHFFFAOYSA-N |
1
Targets
4
Activities
2
Assay Types
0
PK Parameters
20
Publications
4
Known Names
1
Indications
Molecular Properties
249.3
MW (Da)
3.60
ALogP
2
HBA
1
HBD
50.2
PSA (Ų)
0.75
QED
0
Ro5 Violations
2
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| Availability | Withdrawn |
| Chirality | Achiral |
Indications
Gout
ATC Classification
M04AC02
cinchophen
Level 1: MUSCULO-SKELETAL SYSTEM
Level 2: ANTIGOUT PREPARATIONS
Drug Warnings
Withdrawn
hepatotoxicity
Hepatic toxicity, including jaundice, hepatitis and cirrhosis and a greater incidence of gastric ulceration than is associated with other nonsteroidal antiinflammatory agents
Withdrawn
hepatotoxicity
Hepatic toxicity, including jaundice, hepatitis and cirrhosis and a greater incidence of gastric ulceration than is associated with other nonsteroidal antiinflammatory agents
Withdrawn
General Warning
Unfavourable risk-benefit ratio
Withdrawn
hepatotoxicity
Hepatic toxicity, including jaundice, hepatitis and cirrhosis and a greater incidence of gastric ulceration than is associated with other nonsteroidal antiinflammatory agents
Withdrawn
gastrointestinal toxicity
Hepatic toxicity, including jaundice, hepatitis and cirrhosis and a greater incidence of gastric ulceration than is associated with other nonsteroidal antiinflammatory agents
Withdrawn
hepatotoxicity
Hepatic toxicity, including jaundice, hepatitis and cirrhosis and a greater incidence of gastric ulceration than is associated with other nonsteroidal antiinflammatory agents
Withdrawn
hepatotoxicity
Hepatic toxicity, including jaundice, hepatitis and cirrhosis and a greater incidence of gastric ulceration than is associated with other nonsteroidal antiinflammatory agents
Activity Summary
IC50 3 meas.
Kd 1 meas. best 3.9
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A CHEMBL4409 | Kd | 3.9 | 3.9 | 127000.0 | 1 |
Activity Data Samples
Top measurements by pChEMBL value
| Target | Type | Rel. | Value | Units | pChEMBL | Assay | PubMed |
|---|---|---|---|---|---|---|---|
| cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A | Kd | = | 127000.0 | nM | 3.9 | Binding affinity to human PDE10A catalytic domain expressed in Escherichia coli ... | 23509991 |
Literature References
Data from ChEMBL 36 via Core Engine